09/02/2018 21:45:00

Cytori Therapeutics Announces Inducement Grants for New Employees

SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (the “Company”), announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on January 25, 2018 to four (4) new employees (the “Optionees”) exercisable for an aggregate of up to 16,000 shares of the Company's common stock (the “Option Shares”), with a per share exercise price of $0.455, which was the closing price of Cytori’s common stock on the Nasdaq Capital Market on January 25, 2018. The stock options have a ten-year term and vest over a period of four years, with one quarter of the Option Shares vesting on the first anniversary of each Optionee’s employment commencement date with the Company, and with the remainder of the Option Shares vesting over the ensuing three years in thirty-six (36) equal, consecutive, monthly installments, in each case subject to each such Optionee’s continued employment with the Company as of the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2015 New Employee Incentive Plan and the stock option agreements pursuant to which the stock options have been granted.

The stock options were granted as an inducement material to the Optionees’ entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

About Cytori Therapeutics, Inc.

Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit www.cytori.com.

Cytori Therapeutics

, Inc.

Tiago Girao

1.858.458.0900

ir@cytori.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
09 Aug
PNDORA
Pandora kom med ny guidance mandag og Q2-regnskab i dag torsdag.   Her den nye guidance fra i mandag..
57
09 Aug
PNDORA
Du er meget dygtig Portensafe...tillykke med det. Du er sådan et typisk dobbeltalias, som pludselig ..
27
10 Aug
PNDORA
Flere indlæg her på EI, viser i høj grad hvor forelskede, og desperate pandora investorene her på EI..
25
14 Aug
VELO
Vi har diskuteret markedet for immunosuppressive medikamenter før, og jeg har i et tidligere indlæg ..
19
13 Aug
VELO
Husk at markedet er gigantisk! Astellas' to produkter AstagrafXL og Prograf solgte for ca. 12 mia. k..
18
10 Aug
 
Hej Ketty99,   Efter min mening, så 'Ja' vi er overdue, men et aktiemarked kan typisk løbe længere o..
17
10 Aug
VWS
Jeg går ud fra den (måske fejlagtige) antagelse at hele 2018 produktionen allerede stod i ordrebogen..
17
09 Aug
PNDORA
EI smid den tosse Portensafe udfra sitet. Manden er fuldstændig ligegyldig. Tjek om det er en der sk..
17
13 Aug
VELO
Dette er på alle måder et super regnskab. jeg er helt enig med dem der forventer endnu en opjusterin..
16
08 Aug
GEN
Har du nogensinde oplevet, at der udbetales milestone betalinger for samme målepunkt flere gange? :..
16

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Analysis: Positioning to Benefit within Navistar International, Micron Technology, Hewlett Packard Enterprise, American Axle & Manufacturing, Gulfport Energy, and HP — Research Highlights Growth, Revenue, and Consolidated Results
2
Hudson Technologies Enters Into an Interim Waiver and Second Amendment to Its Term Loan Credit and Security Agreement
3
StarVR and Autodesk Bring Break-Through VR to Automotive Design with VRED Optimized for StarVR’s Next-Generation Head Mounted Display
4
Roper Technologies Prices Public Offering Of $700 Million Senior Unsecured Notes Due 2023 And $800 Million Senior Unsecured Notes Due 2028
5
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Oracle Corporation (ORCL)

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
15 August 2018 11:48:01
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180815.2 - EUROWEB3 - 2018-08-15 12:48:01 - 2018-08-15 11:48:01 - 1000 - Website: OKAY